Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. announced on May 13, 2026 that it entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $100.0 million of its common stock from time to time. The offering is registered under the company’s effective Form S-3 (declared effective April 5, 2024) and a prospectus supplement dated May 13, 2026 will be filed. The company also terminated its prior ATM sales agreement with BTIG, LLC effective May 12, 2026.

Key Details

• New ATM program: up to $100,000,000 of common stock may be sold through H.C. Wainwright as agent/principal.
• Selling terms: H.C. Wainwright to receive a 3% commission on gross proceeds; customary expense reimbursements and indemnities apply.
• Prior ATM terminated: the BTIG, LLC agreement (Prior ATM Program) was terminated effective May 12, 2026; no further sales will be made under that program.
• Preliminary liquidity: as of March 31, 2026 Outlook reported approximately $7.7 million in cash and cash equivalents (unaudited, preliminary); this amount excludes $4.5 million of net proceeds received in April 2026 from a registered direct equity offering.

Why It Matters
The new ATM gives Outlook a flexible way to raise up to $100 million of equity capital over time, which can be used to fund operations, reduce cash runway risk or support development programs. However, ATM sales dilute existing shareholders as shares are issued and can put downward pressure on the stock when sold into the market. The company’s reported cash balance ($7.7M preliminary, plus $4.5M April net proceeds not included in that figure) highlights limited near-term liquidity, so access to the ATM could be important for meeting funding needs. All cash figures are preliminary and unaudited and may change when quarterly results are finalized.